Founder, CEO and President
Dr. Michael Fehlings obtained his MD and PhD from the University of Toronto (UofT). He is a staff neurosurgeon at Toronto Western Hospital and senior scientist at the Krembil Research Institute part of the University Health Network, Vice Chair of Research in the Department of Surgery at UofT and Co-Director of the UofT Spine Program. He has received numerous awards including the Olivercrona Award, the Henry Farfan Award and the Richard H. Winn prize. Dr. Fehlings is a fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada
Chief Operating Officer (COO)
Dr. Paul Bradshaw obtained his PhD from the Institute of Cancer Research / Royal Cancer Hospital, University of London, UK where he studied neurological and cancer syndromes. He subsequently undertook further studies in the Program of Genetics and Genome Biology at the Hospital for Sick Children, Toronto, Canada before moving to the Department of Genetic and Development at the Krembil Research Institute. Dr. Bradshaw joined Inteligex in 2018 where he heads corporate development.
Chief Scientific Officer (CSO)
Dr. Mohamad Khazaei obtained his PhD from Muenster University, Germany where he studied the cell and molecular neurobiology. His research is focused on using neural stem/progenitor cells to shed light upon processes that govern neurogenesis during development and regeneration of the injured central nervous system (CNS). Dr. Khazaei joined Inteligex in 2018 where he leads basic science research and development of cell-based strategies to treat spinal cord injury.
Chief Medical Officer (CMO)
Dr. Christopher Ahuja obtained his MD from Queen's University, Canada and is completing his residency training in Neurosurgery at the University of Toronto. He is currently a member of the Surgeon-Scientist Training Program at the University of Toronto where he is specialises in developing translationally-relevant bioengineering human stem cell therapies for spinal cord injury. Dr. Ahuja joined Inteligex in 2018 where he leads translational research and development of the cell therapy pipeline.